Laura Bukavina, MD, MPH
Treatment & Services
- Adrenalectomy
- Inguinal Lymph Node Dissection
- Neobladder Reconstruction
- Nephroureterectomy
- Orchiectomy
- Partial Nephrectomy
- Radical Cystectomy
- Radical Nephrectomy
- Radical Prostatectomy
- Retroperitoneal Lymph Node Dissection
- Robotic Cystectomy
- Robotic Surgery
- Transurethral Resection of Bladder Tumor (TURBT)
Specialty in Diseases & Conditions
- Adrenal Cancer
- Bladder Cancer
- Hereditary Renal Cell Carcinoma
- Kidney Cancer
- Penile Cancer
- Prostate Cancer
- Retroperitoneal Sarcoma
- Testicular Cancer
- Urethral Cancer
Insurance
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.
View All PlansAbout Laura Bukavina, MD, MPH
Dr. Bukavina is an assistant professor of Urologic Oncology at Cleveland Clinic Glickman Urologic Institute, and translational science lead in GU oncology at Cleveland Clinic Lerner College of Medicine. Dr. Bukavina completed her training at Case Western Reserve School of Medicine, followed by a fellowship in urologic oncology at Fox Chase Cancer Center. In addition to her surgical training, she holds a master's degree in epidemiology from Johns Hopkins School of Medicine and a master's degree in immunology and molecular genetics from Drexel. Her educational background reflects her commitment to both surgery and cancer research.
Dr. Bukavina is a recipient of multiple grants and awards for her dedication to bladder and kidney cancer research, including the Robert Wood Johnson Foundation Health Data for Action, Bladder Cancer Advocacy Network Young Investigator, American Urologic Association (AUA) Research Scholar and Society of Women in Urology (SWIU) Elizabeth Pickett Award. She has been recognized for her research evaluating the interplay between genetics, microbiome, and tumor microenvironment. Further, her recognition by the American Association of Cancer Research (AACR) as one of the Top Women in Cancer Research underscores her standing as a pioneering figure among women cancer surgeon scientists.
She serves as an associate editor of European Urology and a member of the editorial board for Urology Times. She also serves on the International Bladder Cancer Network committee and as an expert for kidney cancer for the Society of Immunotherapy of Cancer, underscoring her commitment to advancing research and innovation in bladder and kidney cancer.
Dr. Bukavina is committed to enhancing bladder cancer treatment by pioneering surgical innovations, such as enhancing neobladder procedures and pelvic floor reconstruction with nerve preservation. Additionally, she has extensive experience in hereditary renal cell carcinoma and renal preservation for both primary and recurrent kidney cancer.
On a personal note, Dr. Bukavina's philanthropy is dedicated to providing reconstructive and oncology care in Ukraine. She regularly assists both veterans and refugees with these needs. She has participated in multiple surgical missions to enhance urological care abroad.
Education & Professional Highlights
Appointed
2024
Education & Fellowships
Graduate School - Drexel University
Immunology and Molecular Genetics-
Philadelphia,
PA
2024
Fellowship - Fox Chase Cancer Center
Urologic Oncology
Philadelphia,
PA
2023
Residency - Case Western Reserve University/University Hospitals Case Medical Center
Urology
Cleveland,
OH United States
2021
Graduate School - John Hopkins University
Baltimore,
MD United States
2017
Residency - Case Western Reserve University/University Hospitals Case Medical Center
General Surgery
Cleveland,
OH
2016
Internship - Summa Health
Internal Medicine
Akron,
OH
2014
Medical Education - Northeast Ohio Medical University College of Medicine
Rootstown,
OH
2013
Undergraduate - Cleveland State University
Biology
Cleveland,
OH
2007
Certifications
- Urology
Research & Publications
See publications for Laura Bukavina, MD, MPH.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 5/29/2024, Dr. Bukavina has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
